Online:
Visits:
Stories:
Profile image
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

2017 Forecast – Incretin-Based Drugs Global Market News, Industry Size, Share, Analysis and Research to 2022

Tuesday, March 7, 2017 5:28
% of readers think this story is Fact. Add your two cents.

(Before It's News)

The global Incretin-Based Drugs market is segmented on the basis of drug type, formulation, and geography. On the basis of drug type, market is further segmented into Glucagon-like peptide-1 receptor (GLP-1) agonists and Dipeptidyl Peptidase-4 (DPP-4) inhibitors. According to formulation, the market is segmented into oral and injectable drugs. Geographically, the market is segmented across four regions namely North America, Europe, Asia Pacific and LAMEA.

New product launches and approvals are the few strategies adopted by top industry players. Recently GlaxoSmithKline has launched subcutaneous injection of Tanzeum (albiglutide), a GLP-1 agonist for treatment for type 2 diabetes. In March 2015, Takeda Pharmaceutical got Japanese approval for oral tablet Zafatek, a DPP-4 inhibitor. The companies profiled in the report include, GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co., Inc., AstraZeneca plc, Novartis AG, Eli Lilly and Company, Boehringer Ingelheim GmbH, Takeda Pharmaceutical Company Ltd and Sanofi S.A.

Get Free Sample Report Of Incretin-Based Drugs Market @ http://www.marketresearchstore.com/report/world-incretin-based-drugs-market-opportunities-and-forecasts-68662#RequestSample

Incretins are gut derived hormones, released after the ingestion of food. Incretins are classified into glucagon-like peptide-1 (GLP-1) and gastric inhibitory peptide (GIP). Both the molecules are inactivated by enzyme Dipeptidyl Peptidase-4 (DPP-4). Oral traditional anti-diabetic drugs, often fail to maintain the desired normal level of glucose, especially in the postprandial condition. This has resulted in a strong need for better therapeutics such as incretin based drugs. Incretin not only increases the secretion of insulin by acting on pancreatic beta cells, but also inhibits the release of glucagon by acting on the pancreatic alpha cells. Incretin based drugs namely; Incretin mimetics (GLP-1 agonist) and DPP-4 inhibitors work on the antidiabetic principle of incretin hormone. Incretin based drugs reduce body weight and have better cardiovascular outcomes.

Do Inquiry To Buy Report Of Incretin-Based Drugs Market @ http://www.marketresearchstore.com/report/world-incretin-based-drugs-market-opportunities-and-forecasts-68662#InquiryForBuying

Global Incretin Based Drugs Market – By Drug Type

  • Glucagon-like peptide-1 receptor (GLP-1) agonists
  • Dipeptidyl Peptidase-4 (DPP-4) inhibitors

Global Incretin Based Drugs Market – By Formulation

  • Oral Drugs
  • Injectable Drugs

Global Incretin Based Drugs Market – By Geography

  • North America
  • Europe
  • Asia-Pacific
  • LAMEA

Contact Us:

Joel John
3422 SW 15 Street, Suit #8138,
Deerfield Beach, Florida 33442, USA
USA Tel: +1-386-310-3803
GMT Tel: +49-322 210 92714
USA/Canada Toll Free No.1-855-465-4651
Email: sales@marketresearchstore.com 
Web: http://www.marketresearchstore.com/

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.